Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;55(3):619-639.
doi: 10.1007/s40279-024-02145-7. Epub 2024 Nov 27.

High-Intensity Interval Training for Cancer Patients: A Review of Key Considerations for Exercise Prescription

Affiliations

High-Intensity Interval Training for Cancer Patients: A Review of Key Considerations for Exercise Prescription

Gilmar Dias-da-Silva Jr et al. Sports Med. 2025 Mar.

Abstract

Background: High-intensity interval training (HIIT) performed before, during, and after cancer treatment can attenuate the adverse effects induced by anti-cancer drugs. A clear presentation and rationale of characteristics of HIIT variables is vital to produce the expected HIIT adaptations in cancer patients. However, there are concerns regarding the HIIT protocols used in the cancer literature.

Objectives: The aims were to (1) identify the characteristics of HIIT and the formats that have been prescribed, (2) analyze which anchors have been utilized to prescribe effort and pause intensity, (3) examine characteristics of the physical tests used for HIIT prescription, and (4) identify potential adverse events related to HIIT intervention.

Methods: This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, including PubMed, Scopus, and Web of Science databases.

Results: A total of 51 studies were retrieved, and the following results were found: (1) Only 25 studies reported all four essential variables for HIIT prescription [effort intensity (effort duration): pause intensity (pause duration)]. Of these studies, 23 used active pause and employed the following prescription (on average): [84% (116 s): 39% (118 s)] when percentage of maximal aerobic power (MAP) [maximal/peak oxygen uptake ( V O2max/peak)/MAP] was used; [124% (161 s): 55% (142 s)] when percentage of anaerobic threshold (AT) was used; [83% (230 s): 62% (165 s)] when maximal heart rate percentage (%HRmax) was used. From these 23 studies, 12 used V O2max/peak/MAP (one of the most recommended variables for HIIT prescription). Seven studies adopted the HIIT-long format, and in the remaining five studies, the format was unclear. (2) Twenty-four studies used fractions of V O2max/peak or mechanical variables like MAP as anchors for prescribing effort intensity, two studies used AT, 20 studies used fractions of HRmax/heart rate reserve, two studies used rate of perceived exertion (RPE), while one used RPE and % V O2peak concomitantly, and two studies utilized RPE/%HRmax concomitantly. Two studies utilized passive resting, 12 studies used % V O2peak/%MAP for prescribing pause intensity, four studies used AT, seven studies used %HRmax, one study used %HRmax/% V O2peak, and two studies used absolute loads. (3) Ten studies did not report the characteristics of the physical tests employed, two studies used submaximal tests, and 39 studies utilized graded exercise tests. (4) Ten studies did not report if there were adverse events associated with the exercise program, while 34 studies did not report any adverse events.

Conclusions: Only 50% of the studies provided all the necessary variables for accurate HIIT prescription, raising concerns about the replicability, comprehension, and effective application of HIIT in cancer patients. Most of the studies that reported all variables appeared to have employed the HIIT-long format. Only a few studies used more individualized anchors (e.g., AT) to prescribe HIIT-long format for cancer patients, which is considered a very heterogeneous population.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Author contributions: GDSJ*: Conceptualization; methodology; formal analysis; data curation; writing—original draft; writing—review and editing. VLGP*: Conceptualization; methodology; formal analysis; data curation; writing—original draft; writing—review and editing. SD: Writing—review and editing. MF: writing—review; formal analysis; data curation; editing. GT: Writing—review; formal analysis; data curation; editing. GB: Writing—review. RB: Writing—review; formal analysis; data curation. FV: Writing—review; formal analysis; data curation; editing. MC: Conceptualization; writing—review and editing; supervision and guarantor. All authors contributed to the planning, conduct, and reporting of the work described in this article. All authors read and approved the final version. * Equal contribution. Funding: The authors would like to express gratitude for the São Paulo Research Foundation (FAPESP) grants 2023/02398-3, 2021/01424-5, and 2023/01556-4. VLGP was supported by CAPES/PRINT (process number 88887.716953/2022-00 and 88887.839151/2023-00). Data availability: All data relevant to the study are included in the article or uploaded as online supplemental information.

References

    1. WHO (2018) World health statistics 2018: Monitoring health for the SDGs. WHO. https://digitallibrary.un.org/record/3868813
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 . - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 . - DOI - PubMed
    1. Cancer Treatment | Survivor Facts & Figures | American Cancer Society. (n.d.). Retrieved 3 March 2024, from https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-f...
    1. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;30:135–42. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003451 . - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources